Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition
This study demonstrates that troglitazone has significant therapeutic potential in the treatment of epilepsy by reducing epileptic seizures and the associated brain damage through the inhibition of neuronal ferroptosis. The downregulation of Plaur expression plays a crucial role in TGZ's anti-ferroptotic effect, offering a promising avenue for the development of new epilepsy treatments.
Authors
- Wenting Dai (ORCID: https://orcid.org/0000-0002-8851-5556)
- Shilong Jiang (ORCID: https://orcid.org/0000-0001-6975-0844)
- Wei Zhuo (ORCID: https://orcid.org/0000-0002-8251-4210)
- Xiao‐Yuan Mao (ORCID: https://orcid.org/0000-0002-5149-1204)
- Zhibin Wang (ORCID: https://orcid.org/0000-0002-4950-1995)
- Junyan Liu (ORCID: https://orcid.org/0009-0004-9048-9088)
- Pan Xie
- Zhaoqian Liu (ORCID: https://orcid.org/0000-0001-5724-1516)
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1111/cns.14911
- Citations
- 9
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hunan Province